Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their
exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan …

DNA methylation plays a critical role in establishing and maintaining cellular identity.
However, it is frequently dysregulated during tumor development and is closely intertwined …

Post-translational modifications (PTMs) play key roles in regulating cell signaling and
physiology in both normal and cancer cells. Advances in mass spectrometry enable high …

Despite advancements in treatment protocols, cancer is one of the leading cause of deaths
worldwide. Therefore, there is a need to identify newer and personalized therapeutic targets …

By combining mass-spectrometry-based proteomics and phosphoproteomics with genomics,
epi-genomics, and transcriptomics, proteogenomics provides comprehensive molecular …

Cysteine-focused chemical proteomic platforms have accelerated the clinical development
of covalent inhibitors for a wide range of targets in cancer. However, how different oncogenic …

The connection and causality between cancer and neurodevelopmental disorders have
been puzzling. How can the same cellular pathways, proteins, and mutations lead to …

Cancer is a complex disease composing systemic alterations in multiple scales. In this study,
we develop the Tumor Multi-Omics pre-trained Network (TMO-Net) that integrates multi …

Matching patients to optimal treatment is challenging, in part due to the limited availability of
real-world clinical datasets for predictive biomarker identification. The growing integration of …

Omics techniques generate comprehensive profiles of biomolecules in cells and tissues.
However, a holistic understanding of underlying systems requires joint analyses of multiple …